# NovaTract Surgical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novatract-surgical

- Industry: Medical Devices & Equipment
- Headquarters: New Haven, US
- Website: www.novatract.com
- Total disclosed funding: $3.7M
- Latest round: Series A (Feb 19, 2015)
- Investors on record: 8

## About

NovaTract Surgical develops advanced surgical technology solutions aimed at enhancing patient care and operational efficiency within healthcare settings. Their innovative products support improved clinical outcomes and streamline surgical procedures.Founded in 2010 and headquartered in New Haven, US, NovaTract Surgical specializes in surgical technology solutions. The company has undergone strategic pivots to focus on enhancing surgical procedures and patient outcomes. NovaTract completed its Series A funding in May 2014, receiving USD 0.6 million from investors Connecticut Innovations and Golden Seeds LLC. The company has raised a total of USD 0.6 million, with a current valuation of USD 9.21 mn. The details of the founder’s history are not specified.NovaTract Surgical offers innovative surgical technology products designed to improve operational efficiency and clinical outcomes. Their primary offering includes advanced surgical platforms that enhance precision and facilitate better decision-making in the operating room. The company caters to a wide range of healthcare providers, from small practices to large hospitals, primarily within North America and Europe.Revenue generation for NovaTract Surgical is structured around B2B transactions through a subscription-based model. Clients enter into agreements for various service tiers, with options for annual or monthly billing. Their flagship surgical products are offered under distinct pricing plans, allowing for access by healthcare providers of varying sizes. Strategic partnerships with industry players support revenue growth, integrating NovaTract's solutions into broader healthcare ecosystems.NovaTract Surgical plans to expand its product offerings with new surgical technologies aimed at enhancing patient care, although specific release dates are not detailed. The company is also targeting expansion into new geographic regions to increase its market presence, focusing on both North America and Europe by 2025. The recent Series A funding of USD 0.6 million will support these initiatives by enabling the company to enhance its R&D capabilities and establish a stronger market foothold.

## Funding rounds

- Series A, Feb 19, 2015, $0.6M — Connecticut Innovations, Golden Seeds LLC
- Series A, Feb 19, 2015, $0.6M — Connecticut Innovations, Golden Seeds
- Series A, Jun 14, 2012, $2.4M — Advantage Capital, Connecticut Innovations, LaunchCapital, Enhanced Capital, Golden Seeds, Vital Venture Capital
- Seed, Mar 15, 2011, $0.1M — Advantage Capital, Ironwood Capital

## Investors

- Advantage Capital — Seed, Series A
- Ironwood Capital (https://capitalatlas.ai/funds/ironwood-capital) — Seed
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A
- LaunchCapital (https://capitalatlas.ai/funds/launchcapital) — Series A
- Enhanced Capital (https://capitalatlas.ai/funds/enhanced-capital) — Series A
- Golden Seeds (https://capitalatlas.ai/funds/golden-seeds) — Series A
- Vital Venture Capital (https://capitalatlas.ai/funds/vital-venture-capital) — Series A
- Golden Seeds LLC — Series A